Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration

Analysis from a randomised, double-blind phase II study 11 Medical and Health Sciences 1103 Clinical Sciences

Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Angel H. Bair, Brian I. Rini

Research output: Contribution to journalArticle

Abstract

Background: A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall survival (OS) with axitinib dose titration. Methods: Following a 4-week lead-in period during which all patients received axitinib 5 mg twice-daily (bid); patients meeting the predefined randomisation criteria were randomly assigned to receive axitinib 5 mg bid plus either axitinib or placebo titration. In exploratory analyses, patients were grouped into those who achieved OS ≥24 versus < 24 months, and compared their baseline characteristics with Fisher's exact test or Cochran-Armitage trend exact test, with a 5% significance level. Potential predictive baseline characteristics associated with effect of axitinib dose titration on OS were investigated using a Cox proportional hazard model. Results: Overall, 112 patients were randomised. Three of 56 patients receiving axitinib titration were censored; of the remaining 53, 33 (62%) achieved OS ≥24 months versus 20 (38%) with OS < 24 months. Patients with OS ≥24 vs. < 24 months, respectively, had significantly fewer metastatic sites (≤2 metastases: 52% vs. 10%; ≥3 metastases: 48% vs. 90%), fewer lymph node (45% vs. 75%) or liver (15% vs. 45%) metastases, higher haemoglobin level (i.e., ≥ lower limit of normal: 67% vs. 25%) at baseline, lower neutrophil (≤ upper limit of normal, 97% vs. 75%) and platelet (≤ upper limit of normal, 82% vs. 50%) levels at baseline and ≥ 1 year between histopathological diagnosis and treatment (64% vs. 15%). The primary reason for treatment discontinuation in both OS groups was disease progression. The frequency of toxicity-related discontinuation was comparable between the 2 groups, indicating that it was not a factor for a shorter OS. The multivariate analysis showed that ≥1 year from histopathological diagnosis to treatment and baseline haemoglobin level equal or greater than lower limit of normal were significant covariates associated with favourable OS in patients receiving axitinib titration. Conclusions: The current analyses identified potentially predictive factors that could help selecting patients who may benefit from axitinib dose titration.

Original languageEnglish
Article number17
JournalBMC Cancer
Volume19
Issue number1
DOIs
Publication statusPublished - 2019 Jan 7

Fingerprint

Renal Cell Carcinoma
Health
Survival
Neoplasm Metastasis
Hemoglobins
axitinib
Therapeutics
Random Allocation
Proportional Hazards Models
Disease Progression
Neutrophils
Blood Platelets
Multivariate Analysis
Lymph Nodes
Placebos
Liver

Keywords

  • Axitinib
  • Benefit with dose titration
  • First-line
  • Metastatic renal cell carcinoma
  • Predictive factors
  • Survival benefit

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration : Analysis from a randomised, double-blind phase II study 11 Medical and Health Sciences 1103 Clinical Sciences. / Tomita, Yoshihiko; Uemura, Hirotsugu; Oya, Mototsugu; Shinohara, Nobuo; Habuchi, Tomonori; Fujii, Yosuke; Kamei, Yoichi; Umeyama, Yoshiko; Bair, Angel H.; Rini, Brian I.

In: BMC Cancer, Vol. 19, No. 1, 17, 07.01.2019.

Research output: Contribution to journalArticle

Tomita, Yoshihiko ; Uemura, Hirotsugu ; Oya, Mototsugu ; Shinohara, Nobuo ; Habuchi, Tomonori ; Fujii, Yosuke ; Kamei, Yoichi ; Umeyama, Yoshiko ; Bair, Angel H. ; Rini, Brian I. / Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration : Analysis from a randomised, double-blind phase II study 11 Medical and Health Sciences 1103 Clinical Sciences. In: BMC Cancer. 2019 ; Vol. 19, No. 1.
@article{ba825c0703324333bf81a1ad3e82ea57,
title = "Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: Analysis from a randomised, double-blind phase II study 11 Medical and Health Sciences 1103 Clinical Sciences",
abstract = "Background: A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-na{\"i}ve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall survival (OS) with axitinib dose titration. Methods: Following a 4-week lead-in period during which all patients received axitinib 5 mg twice-daily (bid); patients meeting the predefined randomisation criteria were randomly assigned to receive axitinib 5 mg bid plus either axitinib or placebo titration. In exploratory analyses, patients were grouped into those who achieved OS ≥24 versus < 24 months, and compared their baseline characteristics with Fisher's exact test or Cochran-Armitage trend exact test, with a 5{\%} significance level. Potential predictive baseline characteristics associated with effect of axitinib dose titration on OS were investigated using a Cox proportional hazard model. Results: Overall, 112 patients were randomised. Three of 56 patients receiving axitinib titration were censored; of the remaining 53, 33 (62{\%}) achieved OS ≥24 months versus 20 (38{\%}) with OS < 24 months. Patients with OS ≥24 vs. < 24 months, respectively, had significantly fewer metastatic sites (≤2 metastases: 52{\%} vs. 10{\%}; ≥3 metastases: 48{\%} vs. 90{\%}), fewer lymph node (45{\%} vs. 75{\%}) or liver (15{\%} vs. 45{\%}) metastases, higher haemoglobin level (i.e., ≥ lower limit of normal: 67{\%} vs. 25{\%}) at baseline, lower neutrophil (≤ upper limit of normal, 97{\%} vs. 75{\%}) and platelet (≤ upper limit of normal, 82{\%} vs. 50{\%}) levels at baseline and ≥ 1 year between histopathological diagnosis and treatment (64{\%} vs. 15{\%}). The primary reason for treatment discontinuation in both OS groups was disease progression. The frequency of toxicity-related discontinuation was comparable between the 2 groups, indicating that it was not a factor for a shorter OS. The multivariate analysis showed that ≥1 year from histopathological diagnosis to treatment and baseline haemoglobin level equal or greater than lower limit of normal were significant covariates associated with favourable OS in patients receiving axitinib titration. Conclusions: The current analyses identified potentially predictive factors that could help selecting patients who may benefit from axitinib dose titration.",
keywords = "Axitinib, Benefit with dose titration, First-line, Metastatic renal cell carcinoma, Predictive factors, Survival benefit",
author = "Yoshihiko Tomita and Hirotsugu Uemura and Mototsugu Oya and Nobuo Shinohara and Tomonori Habuchi and Yosuke Fujii and Yoichi Kamei and Yoshiko Umeyama and Bair, {Angel H.} and Rini, {Brian I.}",
year = "2019",
month = "1",
day = "7",
doi = "10.1186/s12885-018-5224-6",
language = "English",
volume = "19",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration

T2 - Analysis from a randomised, double-blind phase II study 11 Medical and Health Sciences 1103 Clinical Sciences

AU - Tomita, Yoshihiko

AU - Uemura, Hirotsugu

AU - Oya, Mototsugu

AU - Shinohara, Nobuo

AU - Habuchi, Tomonori

AU - Fujii, Yosuke

AU - Kamei, Yoichi

AU - Umeyama, Yoshiko

AU - Bair, Angel H.

AU - Rini, Brian I.

PY - 2019/1/7

Y1 - 2019/1/7

N2 - Background: A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall survival (OS) with axitinib dose titration. Methods: Following a 4-week lead-in period during which all patients received axitinib 5 mg twice-daily (bid); patients meeting the predefined randomisation criteria were randomly assigned to receive axitinib 5 mg bid plus either axitinib or placebo titration. In exploratory analyses, patients were grouped into those who achieved OS ≥24 versus < 24 months, and compared their baseline characteristics with Fisher's exact test or Cochran-Armitage trend exact test, with a 5% significance level. Potential predictive baseline characteristics associated with effect of axitinib dose titration on OS were investigated using a Cox proportional hazard model. Results: Overall, 112 patients were randomised. Three of 56 patients receiving axitinib titration were censored; of the remaining 53, 33 (62%) achieved OS ≥24 months versus 20 (38%) with OS < 24 months. Patients with OS ≥24 vs. < 24 months, respectively, had significantly fewer metastatic sites (≤2 metastases: 52% vs. 10%; ≥3 metastases: 48% vs. 90%), fewer lymph node (45% vs. 75%) or liver (15% vs. 45%) metastases, higher haemoglobin level (i.e., ≥ lower limit of normal: 67% vs. 25%) at baseline, lower neutrophil (≤ upper limit of normal, 97% vs. 75%) and platelet (≤ upper limit of normal, 82% vs. 50%) levels at baseline and ≥ 1 year between histopathological diagnosis and treatment (64% vs. 15%). The primary reason for treatment discontinuation in both OS groups was disease progression. The frequency of toxicity-related discontinuation was comparable between the 2 groups, indicating that it was not a factor for a shorter OS. The multivariate analysis showed that ≥1 year from histopathological diagnosis to treatment and baseline haemoglobin level equal or greater than lower limit of normal were significant covariates associated with favourable OS in patients receiving axitinib titration. Conclusions: The current analyses identified potentially predictive factors that could help selecting patients who may benefit from axitinib dose titration.

AB - Background: A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall survival (OS) with axitinib dose titration. Methods: Following a 4-week lead-in period during which all patients received axitinib 5 mg twice-daily (bid); patients meeting the predefined randomisation criteria were randomly assigned to receive axitinib 5 mg bid plus either axitinib or placebo titration. In exploratory analyses, patients were grouped into those who achieved OS ≥24 versus < 24 months, and compared their baseline characteristics with Fisher's exact test or Cochran-Armitage trend exact test, with a 5% significance level. Potential predictive baseline characteristics associated with effect of axitinib dose titration on OS were investigated using a Cox proportional hazard model. Results: Overall, 112 patients were randomised. Three of 56 patients receiving axitinib titration were censored; of the remaining 53, 33 (62%) achieved OS ≥24 months versus 20 (38%) with OS < 24 months. Patients with OS ≥24 vs. < 24 months, respectively, had significantly fewer metastatic sites (≤2 metastases: 52% vs. 10%; ≥3 metastases: 48% vs. 90%), fewer lymph node (45% vs. 75%) or liver (15% vs. 45%) metastases, higher haemoglobin level (i.e., ≥ lower limit of normal: 67% vs. 25%) at baseline, lower neutrophil (≤ upper limit of normal, 97% vs. 75%) and platelet (≤ upper limit of normal, 82% vs. 50%) levels at baseline and ≥ 1 year between histopathological diagnosis and treatment (64% vs. 15%). The primary reason for treatment discontinuation in both OS groups was disease progression. The frequency of toxicity-related discontinuation was comparable between the 2 groups, indicating that it was not a factor for a shorter OS. The multivariate analysis showed that ≥1 year from histopathological diagnosis to treatment and baseline haemoglobin level equal or greater than lower limit of normal were significant covariates associated with favourable OS in patients receiving axitinib titration. Conclusions: The current analyses identified potentially predictive factors that could help selecting patients who may benefit from axitinib dose titration.

KW - Axitinib

KW - Benefit with dose titration

KW - First-line

KW - Metastatic renal cell carcinoma

KW - Predictive factors

KW - Survival benefit

UR - http://www.scopus.com/inward/record.url?scp=85059741527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059741527&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-5224-6

DO - 10.1186/s12885-018-5224-6

M3 - Article

VL - 19

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 17

ER -